longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Asymchem

002821

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 63.55, above the reasonable range, cheaper than 0.13% of the time in the past 3 years, and the industry ranks 115/221, the industry Median 22.98.

63.55xP/E
¥182.48Stock price
¥2.87Earnings per share
63.55xP/E
Stock price¥182.48Earnings per share¥2.87

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
32.94x
Typical range
16.13x–38.60x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 22.98x
019385776

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 22.98x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
002653SZHaisco
75.72x298.55%¥71.88B
002821SZAsymchem
63.55x18.79%¥65.81B
603858SHBUCHANG PHARMA
65.82x--¥15.51B
300723SZApicHope
68.76x255.12%¥15.16B
002399SZHepalink
68.12x109.91%¥13.82B
300049SZFurui Co.,Ltd.
75.99x89.66%¥12.62B
603538SHMenovo
74.38x--¥8.69B
600812SHNCPC
62.98x--¥7.77B
300702SZTIANYU PHARM
78.75x121.95%¥7.13B
688553SHHUIYU PHARMACEUTICAL
60.43x--¥6.85B
603229SHAusun Pharm
77.33x106.25%¥6.27B
002907SZPharscin Pharma
74.71x--¥5.54B
002728SZTY PHAR.
63.02x181.25%¥4.71B
300194SZFuan Pharmaceutical
75.19x--¥4.49B
002644SZFoci Pharmaceutical
70.82x--¥4.17B
002365SZYONGAN PHARMACEUTICAL
76.59x--¥4.09B
000919SZJINLING PHARM.
71.23x--¥3.99B
002693SZSC Pharmaceuticals
69.98x--¥3.58B
300636SZSYNERGY
72.14x0.57%¥2.83B
002566SZYISHENG PHARM
61.25x--¥2.27B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.